Annual Total Liabilities
$14.20 M
-$1.90 M-11.79%
December 31, 2023
Summary
- As of February 8, 2025, SLS annual total liabilities is $14.20 million, with the most recent change of -$1.90 million (-11.79%) on December 31, 2023.
- During the last 3 years, SLS annual total liabilities has fallen by -$3.89 million (-21.52%).
- SLS annual total liabilities is now -82.71% below its all-time high of $82.09 million, reached on December 31, 2013.
Performance
SLS Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$10.61 M
-$1.59 M-13.05%
September 30, 2024
Summary
- As of February 8, 2025, SLS quarterly total liabilities is $10.61 million, with the most recent change of -$1.59 million (-13.05%) on September 30, 2024.
- Over the past year, SLS quarterly total liabilities has dropped by -$3.58 million (-25.23%).
- SLS quarterly total liabilities is now -87.07% below its all-time high of $82.09 million, reached on December 31, 2013.
Performance
SLS Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
SLS Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -11.8% | -25.2% |
| 3 y3 years | -21.5% | -22.7% |
| 5 y5 years | +21.6% | -22.7% |
SLS Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -11.8% | +139.5% | -39.0% | +79.0% |
| 5 y | 5-year | -21.5% | +139.5% | -41.3% | +79.0% |
| alltime | all time | -82.7% | -100.0% | -87.1% | -100.0% |
SELLAS Life Sciences Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $10.61 M(-13.1%) |
| Jun 2024 | - | $12.21 M(-17.2%) |
| Mar 2024 | - | $14.75 M(+3.9%) |
| Dec 2023 | $14.20 M(-11.8%) | $14.20 M(+19.2%) |
| Sep 2023 | - | $11.91 M(-13.2%) |
| Jun 2023 | - | $13.72 M(-13.9%) |
| Mar 2023 | - | $15.94 M(-1.0%) |
| Dec 2022 | $16.09 M(+171.5%) | $16.09 M(+20.1%) |
| Sep 2022 | - | $13.40 M(+1.9%) |
| Jun 2022 | - | $13.15 M(-24.4%) |
| Mar 2022 | - | $17.41 M(+193.7%) |
| Dec 2021 | $5.93 M(-67.2%) | $5.93 M(-47.7%) |
| Sep 2021 | - | $11.35 M(+11.1%) |
| Jun 2021 | - | $10.21 M(-13.7%) |
| Mar 2021 | - | $11.83 M(-34.6%) |
| Dec 2020 | $18.09 M(+72.0%) | $18.09 M(+71.3%) |
| Sep 2020 | - | $10.56 M(-1.6%) |
| Jun 2020 | - | $10.73 M(+19.7%) |
| Mar 2020 | - | $8.96 M(-14.8%) |
| Dec 2019 | $10.52 M(-9.9%) | $10.52 M(-3.1%) |
| Sep 2019 | - | $10.85 M(+1.4%) |
| Jun 2019 | - | $10.70 M(-10.7%) |
| Mar 2019 | - | $11.98 M(+2.6%) |
| Dec 2018 | $11.67 M(-62.9%) | $11.67 M(-41.7%) |
| Sep 2018 | - | $20.01 M(-41.9%) |
| Jun 2018 | - | $34.46 M(-1.0%) |
| Mar 2018 | - | $34.80 M(+10.6%) |
| Dec 2017 | $31.46 M(+175.5%) | $31.46 M(-10.0%) |
| Sep 2017 | - | $34.96 M(-15.6%) |
| Jun 2017 | - | $41.43 M(-4.0%) |
| Mar 2017 | - | $43.14 M(+277.8%) |
| Dec 2016 | $11.42 M(-83.4%) | $11.42 M(-76.7%) |
| Sep 2016 | - | $48.92 M(-8.5%) |
| Jun 2016 | - | $53.46 M(-0.9%) |
| Mar 2016 | - | $53.95 M(-21.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $68.63 M(+58.0%) | $68.63 M(+36.6%) |
| Sep 2015 | - | $50.25 M(-4.5%) |
| Jun 2015 | - | $52.60 M(+6.2%) |
| Mar 2015 | - | $49.52 M(+14.0%) |
| Dec 2014 | $43.43 M(-47.1%) | $43.43 M(-10.7%) |
| Sep 2014 | - | $48.63 M(-6.4%) |
| Jun 2014 | - | $51.97 M(+13.5%) |
| Mar 2014 | - | $45.79 M(-44.2%) |
| Dec 2013 | $82.09 M(+201.5%) | $82.09 M(+44.9%) |
| Sep 2013 | - | $56.63 M(+21.1%) |
| Jun 2013 | - | $46.77 M(+22.6%) |
| Mar 2013 | - | $38.14 M(+40.1%) |
| Dec 2012 | $27.23 M(+30.6%) | $27.23 M(+29.5%) |
| Sep 2012 | - | $21.03 M(+6.0%) |
| Jun 2012 | - | $19.84 M(-48.8%) |
| Mar 2012 | - | $38.78 M(+85.9%) |
| Dec 2011 | $20.86 M(+313.3%) | $20.86 M(-18.6%) |
| Sep 2011 | - | $25.62 M(+13.9%) |
| Jun 2011 | - | $22.49 M(+160.1%) |
| Mar 2011 | - | $8.65 M(+71.4%) |
| Dec 2010 | $5.05 M(-8.4%) | $5.05 M(-20.1%) |
| Sep 2010 | - | $6.32 M(+16.8%) |
| Jun 2010 | - | $5.41 M(-38.9%) |
| Mar 2010 | - | $8.85 M(+60.6%) |
| Dec 2009 | $5.51 M(+296.2%) | $5.51 M(+38.4%) |
| Sep 2009 | - | $3.98 M(+111.9%) |
| Jun 2009 | - | $1.88 M(+25.9%) |
| Mar 2009 | - | $1.49 M(+7.3%) |
| Dec 2008 | $1.39 M(+5.1%) | $1.39 M(+17.0%) |
| Sep 2008 | - | $1.19 M(-22.5%) |
| Jun 2008 | - | $1.53 M(-13.5%) |
| Mar 2008 | - | $1.77 M(+34.0%) |
| Dec 2007 | $1.32 M(>+9900.0%) | $1.32 M(-22.7%) |
| Sep 2007 | - | $1.71 M(>+9900.0%) |
| Dec 2006 | $0.00 | $0.00 |
FAQ
- What is SELLAS Life Sciences annual total liabilities?
- What is the all time high annual total liabilities for SELLAS Life Sciences?
- What is SELLAS Life Sciences annual total liabilities year-on-year change?
- What is SELLAS Life Sciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for SELLAS Life Sciences?
- What is SELLAS Life Sciences quarterly total liabilities year-on-year change?
What is SELLAS Life Sciences annual total liabilities?
The current annual total liabilities of SLS is $14.20 M
What is the all time high annual total liabilities for SELLAS Life Sciences?
SELLAS Life Sciences all-time high annual total liabilities is $82.09 M
What is SELLAS Life Sciences annual total liabilities year-on-year change?
Over the past year, SLS annual total liabilities has changed by -$1.90 M (-11.79%)
What is SELLAS Life Sciences quarterly total liabilities?
The current quarterly total liabilities of SLS is $10.61 M
What is the all time high quarterly total liabilities for SELLAS Life Sciences?
SELLAS Life Sciences all-time high quarterly total liabilities is $82.09 M
What is SELLAS Life Sciences quarterly total liabilities year-on-year change?
Over the past year, SLS quarterly total liabilities has changed by -$3.58 M (-25.23%)